Lucid Diagnostics director buys 245K shares
Lucid Diagnostics Inc. director Dennis Matheis reported an open-market purchase of 245,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lucid Diagnostics Inc. director Dennis Matheis reported an open-market purchase of 245,000 shares of common stock. The weighted average purchase price was $1.0011 per share, with individual trade prices ranging from $0.9375 to $1.0200. Following these purchases, he directly owns 1,033,443 shares.
Insider Trade Summary
Net Buyer: 245,000 shares
Net Buy
1 txn
Insider
Matheis Dennis
Role
Director
Bought
245,000 shs ($245K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 245,000 | $1.0011 | $245K |
Holdings After Transaction:
Common Stock — 1,033,443 shares (Direct)
Footnotes (1)
- F1. The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.9375 to $1.0200, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Key Figures
Shares purchased: 245,000 shares
Weighted average price: $1.0011 per share
Post-transaction holdings: 1,033,443 shares
+1 more
4 metrics
Shares purchased
245,000 shares
Open-market common stock purchase
Weighted average price
$1.0011 per share
Average price for 245,000-share purchase
Post-transaction holdings
1,033,443 shares
Direct ownership after the purchase
Trade price range
$0.9375–$1.0200 per share
Range of individual transaction prices
Key Terms
open-market purchase, weighted average purchase price, non-derivative, Form 4
4 terms
open-market purchase financial
"The transaction is classified as an open-market purchase of common stock."
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"The price reported in Column 4 is a weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
non-derivative financial
"The filing shows this as a non-derivative common stock transaction."
Form 4 regulatory
"What does the Form 4 footnote reveal about the Lucid Diagnostics (LUCD) insider trade prices?"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Lucid Diagnostics (LUCD) director Dennis Matheis report?
Director Dennis Matheis reported buying 245,000 Lucid Diagnostics shares in an open-market purchase. The filing shows this as a non-derivative common stock transaction, indicating he increased his direct equity stake in the company through market purchases.
What does the Form 4 footnote reveal about the Lucid Diagnostics (LUCD) insider trade prices?
The footnote states the reported price is a weighted average for the 245,000 shares. It notes the shares were bought in multiple transactions, with individual trade prices between $0.9375 and $1.0200, and offers to provide detailed trade-by-trade pricing upon request.
Was the Lucid Diagnostics (LUCD) insider transaction an open-market purchase or another type of trade?
The transaction is classified as an open-market purchase of common stock. The Form 4 lists transaction code “P” and describes it as a purchase in an open market or private transaction, confirming it was a straightforward buy rather than an option exercise or gift.
AI-generated analysis. How Rhea-AI works. Not financial advice.
